Aethlon completes 1-for-10 reverse stock split to maintain Nasdaq listing

AETHLON MEDICAL INC

Reverse stock split approved by stockholders and board; ratio 1-for-10.
Effective 5:00 p.m. ET on October 4, 2023; trading begins on split-adjusted basis October 5.
Post-split outstanding shares approximately 2.5 million; new CUSIP 00808Y406.
Purpose: meet Nasdaq minimum bid price requirement and continue capital market access.
No fractional shares issued; stockholders receive full share for any fractional interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.